Efficacy of decitabine in the treatment of myelodysplastic syndrome and its influence on CDH1,P15 methylation and quality of life
Aim To investigate the efficacy of decitabine in the treatment of myelodysplastic syndrome(MDS)and its effects on the methylation level of calcium adhesion molecule 1(CDH1)and P15 and quality of life.Methods Seventy-five MDS patients were randomly divided into control group(37 cases with CAG chemotherapy)and observation group(38 cases with CAG chemotherapy+decitabine).The clinical efficacy,platelet count,hemoglobin,white blood cell count,methylation levels of CDH1 and P15,quality of life and incidence of adverse reactions were compared between the two groups.Results The objective remis-sion rate of observation group was higher than that of control group(P＜0.05).There was no significant difference in the total inci-dence of adverse reactions between the two groups(P＞0.05).Compared with before treatment,the platelet count,hemoglobin,and white blood cell count increased in both groups after treatment;the methylation levels of CDH1 and P15,emotional function,accompa-nying conditions,main symptoms,cognitive level,and satisfaction score decrease;and the changes in the observation group were more significant than those in the control group(P＜0.05).Conclusion Decitabine is effective in the treatment of MDS to downregu-late the methylation level in vivo and improve the quality of life.It does not increase the risk of adverse reactions,and has a high clinical reference value.
dexitabineMDScurative effectmethylationquality of life
万方数据
维普
